KalVista Pharmaceuticals, Inc.
KALV · NASDAQ
9/30/2025 | 7/31/2025 | 4/30/2025 | 1/31/2025 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.19 | -0.46 | -0.23 | -2.20 |
| FCF Yield | -4.98% | -7.51% | -5.85% | -7.00% |
| EV / EBITDA | -13.33 | -11.28 | -10.80 | -7.47 |
| Quality | ||||
| ROIC | -15.54% | -32.92% | -26.08% | -17.05% |
| Gross Margin | 91.00% | 58.63% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.66 | 0.91 | 0.77 | 0.67 |
| Growth | ||||
| Revenue 3-Year CAGR | 2,472,562.15% | 1,125,471.73% | -100.00% | -100.00% |
| Free Cash Flow Growth | 40.31% | -36.93% | -21.96% | 17.46% |
| Safety | ||||
| Net Debt / EBITDA | 2.23 | 2.18 | 1.69 | 3.92 |
| Interest Coverage | -9.68 | -16.75 | -18.70 | -15.11 |
| Efficiency | ||||
| Inventory Turnover | 2.69 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -509.55 | -485.16 | -27.66 | 0.00 |